EarningsCertara's 3Q results came in higher than expectations excluding the services weakness attributed to its regulatory business, with cost management specifically in R&D and S&M offsetting the weakness.
Market PositionCertara is the market leader in PBPK modeling, and there is further expansion opportunity driven by regulatory efforts and efficiency opportunities for biopharma.
Strategic InitiativesManagement highlighted plans to create a fourth software pillar in the Certara suite of offerings, combining its D360 product with Chemaxon to create a tool for customers to use biosimulation to select and optimize molecules.